USE OF COMPOUND CONTAINING TRICYCLIC HETEROARYL

WIPO Patent Application WO/2024/032527

A1

Provided is use of a JAK and SYK kinase inhibitor compound shown in formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof in a drug for treating diseases related to cytokine release syndrome and/or systemic inflammatory response syndrome, especially novel coronavirus pneumonia. The in-vivo and in-vitro research results show that the compound shown in formula (I), the optical isomer thereof, or the pharmaceutically acceptable salt thereof can significantly inhibit the cytokine release induced by novel coronavirus, and has a significant effect on alleviating organ damage induced by inflammatory response. Moreover, the toxicology experiment shows that the compound has a certain safe therapeutic window, has a good clinical application prospect, and provides a new therapeutic option for patients with severe pneumonia (including severe novel coronavirus pneumonia) or severe acute lung injury (such as acute respiratory distress syndrome) and other diseases related to cytokine release syndrome and/or systemic inflammatory response syndrome.

DAN MO (CN)
KANG BIN (CN)
WANG JIAOJIAO (CN)
WANG JIE (CN)
LYU LU (CN)
LU YANLI (CN)
WANG YUQING (CN)

PCT/CN2023/111403

February 15, 2024

August 07, 2023

Click for automatic bibliography generation  

CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)
CSPC OUYI PHARMACEUTICAL CO LTD (CN)

A61K31/5383; A61P11/00; A61P37/02

WO2018108084A1

2018-06-21

US20190255053A1	2019-08-22
US20120053193A1	2012-03-01
CN101401807A	2009-04-08
CN114344316A	2022-04-15
CN114404597A	2022-04-29

BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)

View/Download PDF      PDF Help

Previous Patent: DATA RETRIEVAL PROCESSING METHOD AND SYSTEM

Next Patent: HOT STAMPED PART HAVING EXCELLENT LOW-TEMPERATURE BRITTLENESS RESISTANCE AND MANUFACTURING METHOD TH...